ArticleGenes2015
How Porin Heterogeneity and Trade-Offs Affect the Antibiotic Susceptibility of Gram-Negative Bacteria.
Article in Genes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Interplay between porin deficiency, fitness, and virulence in carbapenem-non-susceptible Pseudomonas aeruginosa and Enterobacteriaceae.PLoS pathogens · 2025Review
- Antimicrobial Activity of Naturally Occurring and Semi-Synthetic Chlorinated Compounds.Mini reviews in medicinal chemistry · 2025Review
- Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Mechanisms of low susceptibility to the disinfectant benzalkonium chloride in a multidrug-resistant environmental isolate ofFrontiers in microbiology · 2023Article
- CRISPR-Cas System: A Tool to Eliminate Drug-Resistant Gram-Negative Bacteria.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Identification of Antigenic Properties of Acinetobacter baumannii Proteins as Novel Putative Vaccine Candidates Using Reverse Vaccinology Approach.Applied biochemistry and biotechnology · 2022Article
- Article
- Differential Expression ofMolecules (Basel, Switzerland) · 2021Article
- Evaluation of the BD Phoenix CPO detect panel for prediction of Ambler class carbapenemases.Scientific reports · 2021Article
- Microevolution in the major outer membrane protein OmpA ofMicrobial genomics · 2020Article
- Stepwise evolution and convergent recombination underlie the global dissemination of carbapenemase-producing Escherichia coli.Genome medicine · 2020Article
- Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion.eLife · 2019Article
- Host adaptation and convergent evolution increases antibiotic resistance without loss of virulence in a major human pathogen.PLoS pathogens · 2019Article
- The fitness costs and trade-off shapes associated with the exclusion of nine antibiotics by OmpF porin channels.The ISME journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Variations in porin proteins are common in Gram-negative pathogens. Altered or absent porins reduce access of polar antibiotics across the outer membrane and can thus contribute to antibiotic resistance. Reduced permeability has a cost however, in lowering access to nutrients. This trade-off between permeability and nutritional competence is the source of considerable natural variation in porin gate-keeping. Mutational changes in this trade-off are frequently selected, so susceptibility to detergents and antibiotics is polymorphic in environmental isolates as well as pathogens. Understanding the mechanism, costs and heterogeneity of antibiotic exclusion by porins will be crucial in combating Gram negative infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.